Naratriptan Beta (Naratriptan)

Naratriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors. By stimulating these receptors, it causes constriction of cranial blood vessels and blocks the release of inflammatory neuropeptides, interrupting the pain pathway that generates migraine.

The dosage of Naratriptan is determined by the prescribing clinician based on individual patient factors. The prescriber selects the appropriate strength and timing, typically using the lowest effective dose to manage each migraine attack.

Safety data for Naratriptan during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naratriptan has a longer half‑life than sumatriptan, which may provide extended migraine relief with fewer doses. Both belong to the same drug class and share similar mechanisms, but individual response, side‑effect profile and drug‑interaction potential can differ, so clinicians choose based on patient history and tolerability.

Store Naratriptan Beta tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Naratriptan Beta is taken orally as a whole tablet with a glass of water. It should be swallowed whole, not chewed or crushed, and is usually taken as soon as migraine symptoms begin for optimal effectiveness.

Serious risks include chest pain or tightness, hypertension, serotonin syndrome, severe allergic reactions, cardiac arrhythmias, and rare ischemic events such as stroke or myocardial infarction. Patients should seek immediate medical attention if any of these symptoms occur.

Naratriptan is contraindicated in patients with uncontrolled hypertension, significant cardiovascular disease (including coronary artery disease, stroke, or peripheral vascular disease), severe hepatic impairment, and in those who have previously experienced an allergic reaction to Naratriptan or any other triptan.